Stockpolly
Search
IRMD · NASDAQ · Medical - Devices

IRadimed

Builds non-magnetic infusion, monitoring, and safety devices for MRI environments.

$87.07
After-hours close+0.03 (+0.03%)
At close$87.04(+0.05%)
Loading prices…

Something off on this page? Send us feedback.

Profile

IRadimed CorporationIRMDHealth Care

Sells MRI-compatible infusion pumps, patient vital signs monitors, ferromagnetic detection systems, disposable tubing, and service plans. The business is a single-segment medical-device franchise with U.S.-heavy sales and product timing shaped by FDA clearance.

Designs and manufactures MRI-compatible medical devices for hospitals and acute-care facilities, centered on MRidium IV infusion pumps and the 3880 patient vital signs monitor. Related revenue comes from proprietary disposable tubing, extended maintenance, service, and the FMD1 ferromagnetic detection system for MRI-zone safety.

Sales are concentrated in the United States, where the company uses a direct field organization; international markets are served through independent distributors. The operating model is narrow: management reports a single MRI-compatible medical-device segment rather than separate product divisions.

Execution depends on non-magnetic device engineering, FDA clearance for regulated U.S. products, and a product upgrade cycle around the newer MRidium pump. The business also depends on a limited product set, specialized suppliers, a single Florida facility, and founder-led management.

Company facts

CEORoger Susi
ListedJul 16, 2014
ExchangeNASDAQ
HeadquartersOrlando, FL
CountryUnited States
Employees166
CIK0001325618
ISINUS46266A1097

Categories

Key statistics

Market cap$1.11B
EPS (ttm)$1.79
P/E (ttm)48.64
ROE23.5%
P/B10.94
P/S12.89
Dividend yield0.88%
Beta0.63vs XLV 0.42

Year to date −8.9% · Average volume (30d) 117.1K

Analysts

Price target, next 12 months$120.00+37.8%Median of 2 analysts · vs the Aug 28 close
ConsensusBuy2 of 2 analysts rate it buy or better

Ratings

Target range

Latest analyst notes

DateFirmActionPrior targetTarget
Feb 11, 2026Lake StreetTarget$100$120
Feb 10, 2026Roth CapitalTarget$98$120
Nov 3, 2025Roth CapitalTarget$90$98
Nov 3, 2025Lake StreetTarget$100
Oct 31, 2025Roth CapitalTarget$60$90

Earnings

EPS

Estimate$0.52
ReportedDue Nov 2, 2026

Revenue

Estimate$23.2M
ReportedDue Nov 2, 2026

History

Report dateEPS estEPSSurpriseRevenue estRevenueSurpriseNext session
Jul 31, 2026Q2 FY26$0.44$0.46+4.5%$20.4M$20.5M+0.6%−4.57%
May 1, 2026Q1 FY26$0.42$0.49+16.7%$21.3M$22.0M+3.1%−2.56%
Feb 10, 2026Q4 FY25$0.49$0.54+10.2%$21.6M$22.7M+5.1%−1.97%
Nov 3, 2025Q3 FY25$0.48$0.47−2.1%$21.6M$21.2M−1.8%+3.13%
View details

Financial highlights

12 quartersQ1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
Revenue$19.5M$20.4M$21.2M$22.7M$22.0M$20.5M
Gross profit$14.8M$16.0M$16.5M$17.0M$16.8M$15.2M
Operating income$5.4M$6.8M$6.8M$7.1M$7.2M$6.4M
Net income$4.7M$5.8M$5.6M$6.4M$5.8M$5.2M
Diluted EPS$0.37$0.45$0.43$0.50$0.45$0.41
Gross margin76.1%78.2%77.8%75.1%76.5%74.1%
Operating margin27.8%33.3%32.2%31.3%32.9%31.2%

Fiscal years (4-quarter sums)FY21 $41.8M · FY22 $53.3M · FY23 $65.6M · FY24 $73.2M · FY25 $83.8M

Revenue by product · Q2 FY26

Device Revenue$13.8M · 64%
MRI Compatible Patient Vital Signs Monitoring Systems$6.7M · 31%
Service$1.1M · 5%

Revenue by geography · Q2 FY26

United States$16.7M · 82%
Non-US$3.7M · 18%

Balance sheet, Jun 30, 2026Cash & short-term investments $59.1M · Total debt $0 · Total assets $115.0M · Shareholders' equity $101.7M

Dividends

Next ex-date
Nov 14, 2026
estimated · in 77 days
Annual dividend
$0.77
per share
Dividend yield
0.88%
Schedule
Quarterly
4 payments a year

Last raised to $0.20 from $0.17 in Feb 2026. To collect a payout, hold shares through the close before the ex-date.

History

Ex-dateRecordPaidAmountNote
Aug 14, 2026Aug 14Aug 28$0.20
May 15, 2026May 15May 29$0.20
Feb 23, 2026Feb 23Mar 6$0.20raised from $0.17
Dec 17, 2025Dec 17Dec 30$0.50special dividend
Nov 14, 2025Nov 14Nov 25$0.17
Aug 18, 2025Aug 18Aug 28$0.17
May 20, 2025May 20May 30$0.17
Feb 24, 2025Feb 24Mar 5$0.17raised from $0.15
View details

Ownership

Institutions 69.35%8.86M sharesInsiders 17.46%2.23M sharesOther 13.19%1.69M shares

Shares outstanding 12.78M · Float 8.33M · 65.1% free float

Top shareholders13F · 13D/G · Form 4

HolderShares% outstandingFormFiled
Roger E. Susi · director, 10 percent owner, officer: CEO, President, Chairman2.16M16.92%Form 4Jun 2, 2026
BlackRock, Inc.967.8K7.57%13FAug 7, 2026
Kayne Anderson Rudnick Investment Management LLC397.0K3.11%13FAug 13, 2026
Renaissance Technologies LLC394.4K3.09%13FAug 13, 2026
Copeland Capital Management, LLC391.9K3.07%13FAug 4, 2026

Insider tradesForm 4

DateInsiderRoleSharesAvg price
Jun 4, 2026Hilda Frederique Scharen-Guiveldirector−3,000$95.00
Jun 1, 2026Roger E. Susidirector, 10 percent owner, officer: CEO, President, Chairman−2,500$90.60
May 27, 2026Roger E. Susidirector, 10 percent owner, officer: CEO, President, Chairman−2,500$91.95
May 26, 2026Roger E. Susidirector, 10 percent owner, officer: CEO, President, Chairman−5,000$92.23
May 19, 2026Roger E. Susidirector, 10 percent owner, officer: CEO, President, Chairman−2,500$87.88
View details

Peers

  • Philips (ADR)

    Dominant MRI patient-monitor rival through Invivo

  • GE HealthCare

    Large imaging vendor with MRI-monitoring overlap

  • BD

    Conventional infusion-system rival in MRI workarounds

  • Baxter International

    Connected infusion pumps for outside-room workarounds

  • ICU Medical

    Pure-play infusion company with Plum pump overlap

CompareAfter-hours close

CompanyPriceChange
IRadimed$87.07+0.03%$1.11B48.637.312.9+0.3%
Philips (ADR)$26.72+0.06%$26.12B19.913.71.3−2.9%
GE HealthCare$71.73−0.01%$32.40B20.813.81.6+5.8%
BD$189.00−0.27%$52.22B57.114.32.5−9.6%
Baxter International$26.30+0.65%$13.51B—12.51.2+5.3%
ICU Medical$175.10+0.01%$4.38B148.419.72.0−0.2%
Median38.913.81.6−0.2%